Roche Holding Ag: Funding the Genentech Acquisition

16 Pages Posted: 30 May 2017 Last revised: 27 Nov 2018

See all articles by Michael J. Schill

Michael J. Schill

University of Virginia - Darden School of Business

Brett Durick

affiliation not provided to SSRN

Drew Chambers

affiliation not provided to SSRN

Multiple version iconThere are 2 versions of this paper

Abstract

This case examines the decision by the Swiss pharmaceutical Roche Holding AG (Roche) to offer a record $42 billion bond in February 2009. In light of a pending acquisition of US biotechnology leader Genentech, Roche management planned to sell $32 billion in bonds at various maturities from 1 year to 30 years and in three different currencies (US dollar, euro, and British pound). In a context of substantial uncertainty in both world financial markets and the value of the Genentech deal, students are introduced to the pricing of corporate bonds by being invited to price Roche's bold global offering.

Excerpt

UVA-F-1645

Rev. Nov. 8, 2018

Roche Holding AG: Funding the Genentech Acquisition

We are confident that we will have the financing available when the money is needed…The plan is to use as financing partly our own funds and then obviously bonds and then commercial paper and traditional bank financing. We will start by going to the bond market first.

—Roche Chairman Franz Hume

In July 2008, Swiss pharmaceutical company Roche Holding AG (Roche) made an offer to acquire all remaining outstanding shares of US biotechnology leader Genentech for (US dollars) USD89.00 per share in cash. Six months later, with equity markets down 35%, Roche announced its recommitment to the deal with a discounted offer of USD86.50 in cash per share of Genentech stock.

. . .

Keywords: cost of debt, risk premium, bond math, credit ratings, default risk

Suggested Citation

Schill, Michael J. and Durick, Brett and Chambers, Drew, Roche Holding Ag: Funding the Genentech Acquisition. Darden Case No. UVA-F-1645. Available at SSRN: https://ssrn.com/abstract=2974470

Michael J. Schill (Contact Author)

University of Virginia - Darden School of Business ( email )

P.O. Box 6550
Charlottesville, VA 22906-6550
United States
434-924-4071 (Phone)
434-243-7676 (Fax)

HOME PAGE: http://www.darden.virginia.edu/faculty/schill.htm

Brett Durick

affiliation not provided to SSRN

No Address Available

Drew Chambers

affiliation not provided to SSRN

No Address Available

Register to save articles to
your library

Register

Paper statistics

Downloads
2
Abstract Views
469
PlumX Metrics
!

Under construction: SSRN citations will be offline until July when we will launch a brand new and improved citations service, check here for more details.

For more information